X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Bavituximab is an antibody designed to reverse immune suppression by inhibiting phosphatidylserine (PS) signaling. Bavituximab blocks tumor immune suppression signaling from PS to multiple immune cell receptor families.
Lead Product(s): Bavituximab,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2023
Details:
Results showed MEDI4736 (durvalumab) maintenance therapy did not prolong PFS or OS compared to active surveillance in HER2-negative patients unselected for PD-L1 status.
Lead Product(s): Durvalumab
Therapeutic Area: Oncology Product Name: MEDI4736
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Royal Marsden NHS Foundation Trust
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Navicixizumab is an anti-DLL4/VEGF bispecific antibody product candidate that demonstrated antitumor activity in patients who were previously treated with Avastin® (bevacizumab) in a Phase 1b clinical trial.
Lead Product(s): Navicixizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
Treatment led to depletion of immunosuppressive myeloid-derived suppressor cells within the tumor microenvironment, suggesting bavituximab may synergistically combine with checkpoint inhibitors.
Lead Product(s): Bavituximab,Temozolomide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: National Comprehensive Cancer Network
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
Overall response rate (ORR) of 43% and median duration of response of 6 months seen with an anti-DLL4/VEGF bispecific antibody, navicixizumab in combination with paclitaxel heavily pretreated platinum-resistant ovarian cancer patients.
Lead Product(s): Navicixizumab,Paclitaxel
Therapeutic Area: Oncology Product Name: OMP-305B83
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
